TG THERAPEUTICS INC (TGTX)

US88322Q1085 - Common Stock

32.16  -0.1 (-0.31%)

After market: 32.8058 +0.65 (+2.01%)

TG THERAPEUTICS INC

NASDAQ:TGTX (12/24/2024, 7:41:00 PM)

After market: 32.8058 +0.65 (+2.01%)

32.16

-0.1 (-0.31%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%-97.26%
Sales Q2Q%-49.41%
CRS94.79
6 Month80.78%
Overview
Earnings (Last)11-04 2024-11-04/bmo
Earnings (Next)N/A N/A
Ins Owners9.59%
Inst Owners61.18%
Market Cap5.01B
Shares155.67M
PEN/A
Fwd PE32.72
Dividend YieldN/A
Analysts80
Short Float %20.64%
Short Ratio9.35
IPO12-14 1995-12-14
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

TGTX Daily chart

Company Profile

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in Morrisville, North Carolina and currently employs 319 full-time employees. The firm is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. The company is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. The company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.

Company Info

TG THERAPEUTICS INC

3020 Carrington Mill Blvd., Suite 475

Morrisville NORTH CAROLINA 10014

P: 18775758489

CEO: Michael S. Weiss

Employees: 300

Website: https://www.tgtherapeutics.com/

TGTX News

News Image13 days ago - Market News VideoInteresting TGTX Put And Call Options For January 2025
News Imagea month ago - TG Therapeutics, Inc.TG Therapeutics to Participate in the Evercore HealthCONx Conference

Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET...

News Imagea month ago - TG Therapeutics, Inc.TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced it ranked number one on the Deloitte Technology Fast...

News Imagea month ago - Market News VideoNoteworthy Wednesday Option Activity: CVNA, AAP, TGTX
News Image2 months ago - Investor's Business DailyStock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review

A Fed rate cut and a slew of big earnings reports filled out a busy week.

News Image2 months ago - Investor's Business DailyTG Therapeutics Crashes — Reversing A Breakout — On Its Mixed Third-Quarter Results

The company raised its sales outlook for the year, though, following stronger-than-expected revenue from its only product.

TGTX Twits

Here you can normally see the latest stock twits on TGTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example